Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. |
40.00% |
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. |
50.00% |
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. |
70.00% |
Beta-solamarine: tumor inhibitor isolated from Solanum dulcamara. |
60.00% |
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. |
60.00% |
Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. |
80.00% |
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. |
80.00% |
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary |
50.00% |
Ukrain (NSC-631570) influences on bone status: a review. |
50.00% |
A comparative evaluation of the influence of the complex drug Ukrain and its components on the effects of radiation |
80.00% |
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... |
50.00% |
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses |
70.00% |
A study of the influence of a novel drug Ukrain on in vivo effects of low-dose ionizing radiation |
50.00% |
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. |
80.00% |
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. |
80.00% |
Antinociceptive effect of ten day administration of Ukrain in mice and interaction of the treatment with morphine |
80.00% |
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. |
50.00% |
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemi |
70.00% |
BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
70.00% |
Biological activity of some thiophosphamide derivatives of alkaloids with respect to influenza virus |
50.00% |
Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model |
50.00% |
Cancer preventive effect of Morinda citrifolia (Noni). |
70.00% |
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy |
50.00% |
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. |
40.00% |
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. |
90.00% |
Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. |
30.00% |
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. |
60.00% |
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a |
90.00% |
Does the Ukrain preparation protect mice against lethal doses of bacteria? |
60.00% |
Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells |
70.00% |
Effect of Ukrain on the efficacy of anti-epileptic drugs against maximal electroshock-induced seizures in mice. |
30.00% |
Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regi |
80.00% |
Effects of a high molecular mass Convolvulus arvensis extract on tumor growth and angiogenesis. |
90.00% |
Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. |
75.00% |
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multipl |
80.00% |
Enhancement of macrophage tumouricidal activity by the alkaloid derivative |
40.00% |
Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer. |
50.00% |
Gastric cancer originating from bone marrow-derived cells. |
70.00% |
Generation of biologically active retro-genes upon interaction of mouse spermatozoa with exogenous DNA |
70.00% |
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP |
60.00% |
Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. |
80.00% |
Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. |
60.00% |
Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. |
40.00% |
Increased Response to Ketamine Following Treatment at Long Intervals: Implications for Intermittent Use. |
60.00% |
Influence of Ukrain on the nuclear thyroid hormone receptors after short-term gamma-irradiation. |
50.00% |
Inhibition of angiogenesis of LCI-D20 hepatocellular carcinoma by metronomic chemotherapy of S-1 |
50.00% |
Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. |
50.00% |
Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angio.. |
60.00% |
Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. |
70.00% |
Interaction between Ukrain and Naltrexone in the writhing syndrome test in mice |
80.00% |
Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. |
55.00% |
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. |
70.00% |
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. |
80.00% |
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. |
90.00% |
Modification of antinociceptive action of morphine by Ukrain in rodents |
50.00% |
Morphometric and kinetic analysis of the growth of experimental sarcoma-45 in the presence of Ukrain |
50.00% |
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. |
70.00% |
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell |
90.00% |
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell c |
80.00% |
Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytot..... |
80.00% |
Preclinical antitumor and antiangiogenic activity of a metronomic schedule of cisplatin against human transitional cell carcinom |
50.00% |
Preliminary pharmacokinetic studies of Ukrain in rats |
|
Propolis Extract (Bio 30) Suppresses the Growth of Human Neurofibromatosis (NF) Tumor Xenografts in Mice |
55.00% |
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
70.00% |
Six-week treatment with Ukrain in rabbits. Part I: Morphological parameters |
50.00% |
Six-week treatment with Ukrain in rabbits. Part II: Serum levels of gonadal hormones |
20.00% |
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones |
|
Some pharmacological properties of prolonged administration of Ukrain in rodents |
50.00% |
Sorafenib and radiation: A promising combination in colorectal and pancreas cancer |
70.00% |
Strong synergy of heat and modulated electromagnetic field in tumor cell killing. |
60.00% |
Synergistic activity of PHY906 with capecitabine in pancreatic carcinoma. |
80.00% |
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. |
70.00% |
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt |
80.00% |
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
Teratological evaluation of Ukrain in hamsters and rats |
|
The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 ... |
80.00% |
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. |
80.00% |
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary stu |
60.00% |
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs |
20.00% |
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing |
|
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect |
60.00% |
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy |
30.00% |
Theoretical grounds and experimental confirmation of the antiviral effect of the |
60.00% |
Tolerance to the anticonvulsant effect of morphine in mice: blockage by ultra-low dose naltrexone. |
60.00% |
Ukrain: acute toxicity after intravenous, intramuscular and oral administration in rats |
40.00% |
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. |
90.00% |